<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30091683</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1423-0380</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>40</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</Title>                <ISOAbbreviation>Tumour Biol.</ISOAbbreviation>            </Journal>            <ArticleTitle>miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro.</ArticleTitle>            <Pagination>                <MedlinePgn>1010428318791887</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1010428318791887</ELocationID>            <Abstract>                <AbstractText>Effectively targeting cancer stem cells, a subpopulation of tumorigenic, aggressive, and radioresistant cells, holds therapeutic promise. However, the effects of the microRNA miR-142-3p, a small endogenous regulator of gene expression on breast cancer stem cells, have not been investigated. This study identifies the influence of miR-142-3p on mammary stemness properties and breast cancer radioresistance to establish its role in this setting. miR-142-3p precursor transfection was performed in MDA-MB-468, HCC1806, and MCF-7 cells, and stem cell markers CD44, CD133, ALDH1 activity and mammosphere formation were measured. β-catenin, the canonical wnt signaling effector protein, was quantified by Western blots and cell fluorescence assays both in miR-142-3p-overexpressing and anti-miR-142-3p-treated cells. Radiation response was investigated by colony formation assays. Levels of BRCA1, BRCA2, and Bod1 in miR-142-3p-overexpressing cells as well as expression of miR-142-3p, Bod1, KLF4, and Oct4 in sorted CD44<sup>+</sup>/CD24<sup>-/low</sup> cells were determined by quantitative polymerase chain reaction. miR-142-3p overexpression resulted in a strong decline in breast cancer stem cell characteristics with a decrease in CD44, CD133, ALDH1, Bod1, BRCA2, and mammosphere formation as well as reduced survival after irradiation. miR-142-3p expression was strongly reduced in sorted CD44<sup>+</sup>/CD24<sup>-/low</sup> stem cells, while Bod1, Oct4, and KLF4 were overexpressed. β-catenin levels strongly decreased after miR-142-3p overexpression, but not after anti-miR-142-3p treatment. We conclude that miR-142-3p downregulates cancer stem cell characteristics and radioresistance in breast cancer, mediated by a reduced role of β-catenin in miR-142-3p-overexpressing cells. miR-142-3p might therefore help to target cancer stem cells.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Troschel</LastName>                    <ForeName>Fabian M</ForeName>                    <Initials>FM</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0001-5066-6650</Identifier>                    <AffiliationInfo>                        <Affiliation>1 Department of Radiation Therapy-Radiation Oncology, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Böhly</LastName>                    <ForeName>Nicolas</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Radiation Therapy-Radiation Oncology, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Borrmann</LastName>                    <ForeName>Katrin</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Radiation Therapy-Radiation Oncology, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Braun</LastName>                    <ForeName>Timo</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Radiation Therapy-Radiation Oncology, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schwickert</LastName>                    <ForeName>Alexander</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kiesel</LastName>                    <ForeName>Ludwig</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eich</LastName>                    <ForeName>Hans Theodor</ForeName>                    <Initials>HT</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Radiation Therapy-Radiation Oncology, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Götte</LastName>                    <ForeName>Martin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Greve</LastName>                    <ForeName>Burkhard</ForeName>                    <Initials>B</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-0331-8108</Identifier>                    <AffiliationInfo>                        <Affiliation>1 Department of Radiation Therapy-Radiation Oncology, University Hospital Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Tumour Biol</MedlineTA>            <NlmUniqueID>8409922</NlmUniqueID>            <ISSNLinking>1010-4283</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C555159">MIRN142 microRNA, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011836" MajorTopicYN="Y">Radiation Tolerance</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">cancer stem cells</Keyword>            <Keyword MajorTopicYN="N">mammospheres</Keyword>            <Keyword MajorTopicYN="N">miR-142-3p</Keyword>            <Keyword MajorTopicYN="N">radiation</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30091683</ArticleId>            <ArticleId IdType="doi">10.1177/1010428318791887</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>